Martin Marino Purchases 115,000 Shares of Microbix Biosystems (TSE:MBX) Stock

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino acquired 115,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were bought at an average cost of C$0.28 per share, with a total value of C$32,200.00. Following the completion of the acquisition, the director directly owned 2,000,167 shares in the company, valued at C$560,046.76. The trade was a 6.10% increase in their position.

Martin Marino also recently made the following trade(s):

• On Tuesday, May 26th, Martin Marino acquired 69,000 shares of Microbix Biosystems stock. The shares were bought at an average cost of C$0.26 per share, with a total value of C$17,940.00.
• On Wednesday, May 27th, Martin Marino acquired 24,500 shares of Microbix Biosystems stock. The shares were bought at an average cost of C$0.26 per share, with a total value of C$6,370.00.

Microbix Biosystems Stock Performance

TSE MBX opened at C$0.27 on Friday. Microbix Biosystems Inc. has a 52-week low of C$0.21 and a 52-week high of C$0.34. The company has a debt-to-equity ratio of 27.03, a quick ratio of 5.57 and a current ratio of 5.35. The company has a market capitalization of C$37.13 million, a P/E ratio of -6.59 and a beta of 0.48. The company has a fifty day moving average of C$0.24 and a 200-day moving average of C$0.24.

Microbix Biosystems (TSE:MBX) last posted its quarterly earnings data on Thursday, May 14th. The company reported C($0.01) earnings per share (EPS) for the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%.The company had revenue of C$3.38 million for the quarter. As a group, equities research analysts predict that Microbix Biosystems Inc. will post 0.02 EPS for the current fiscal year.

About Microbix Biosystems

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.